World Health Organization (“WHO”) Authorizes a Vivo Portfolio Company Sinovac Biotech, for Emergency Use
-
Vivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals GalleryVivo Capital’s venture portfolio company AADI announces a merger agreement with Aerpio Pharmaceuticals with a concurrent $155M in PIPE financing by Aerpio Pharmaceuticals
Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work
Bolt Biotherapeutics strikes a major upsized $230M IPO [...]
Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health
Vivo Capital and an Investor Syndicate Completes Sale [...]
Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B
Vivo Capital's Portfolio Company, Preventice was Bought [...]